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There are increasing numbers of reports of incidentally
detected, asymptomatic venous thromboembolisms (VTE) in
patients undergoing chest or abdominal computed tomography
(CT) for reasons other than a clinical suspicion of either a deep
vein thrombosis (DVT) or a pulmonary embolism (PE). The
increasing frequency of these incidental ﬁndings is probably
because of the introduction of multi-detector computed
tomography (CT) scanners with high acquisition speeds,
increased spatial resolution and resultant improved visualiza-
tion of abdominal vein and peripheral pulmonary arteries [1,2].
The detection of asymptomatic VTE is becoming a partic-
ular clinical problem with CT scans performed for cancer
staging [3–5]. In a recent systematic, we estimated a prevalence
of asymptomatic PE of 3.2% in patients undergoing a CT scan
for staging of the disease [6].
Symptomatic VTE predicts poorer prognosis in patients
with cancer [7]. In a recent retrospective study, survival rates of
cancer patients with an unsuspected, asymptomatic PE found
on a routine cancer staging CT scan were found to be lower
than in matched patients without an asymptomatic PE [8].
Thus, an asymptomatic VTE in cancer patients found during
staging of the disease may be an important prognostic marker
that might inﬂuence management strategies.
To explore this clinical issue, we performed a multicenter-
retrospective study with the aim of comparing 6-month
survival rates in a group of 60 cancer patients with an
incidentally detected asymptomatic VTE, in a group of 120
cancer patients with a symptomatic VTE, and in a group of 60
cancer patients in whom a VTE was excluded.
An asymptomatic VTE was deﬁned as the detection of an
unsuspected PE or DVT on a CT scan. Scans were usually
ordered by the treating oncologist during baseline staging, or to
determine treatment effect after a deﬁned duration of therapy.
A symptomatic VTE was objectively diagnosed according to
commonly accepted criteria [9,10]. In all patients with a PE,
either incidentally detected or symptomatic, a compression
ultrasound of the lower limbs was performed. In the third
group, a clinically suspected VTE had to be objectively
excluded by commonly accepted criteria [9,10].
All included patients had been referred to the anticoagula-
tion clinics of the study centers (Varese, Ancona, Piacenza and
Palermo, Italy) between January 2007 and September 2008.
Classiﬁcation of patients as asymptomatic or symptomatic was
done locally, without central adjudication. Patients with a prior
VTE were excluded.
At each participating center, all VTE patients are monitored
regularly for morbid outcomes, and information on clinical
events is documented and registered in computerized databas-
es. All patients are reviewed regularly in their local Oncology
Department.
At each center, medical records of patients were reviewed by
a trained physician for patient demographics, type and
histology of the primary malignancy, presence and sites of
metastases, concomitant chemotherapy, hormonal therapy,
radiotherapy, therapy with erythropoietin and use, type and
dose of anticoagulant therapy. Data extraction from the
medical records was performed using selection criteria and data
collection forms that were prepared before the chart reviews.
Information on 6-month mortality in the three groups was
obtained for all patients.
Baseline characteristics of patients were compared using
Students t-test (for continuous variables) and the v2- or
Fishers exact test (for dichotomous variables). Six-month
mortality was calculated in each group.Differences inmortality
rates were ﬁrst considered taking into account patients with
and without thrombosis. Afterwards, the rates were compared
among the three groups. Finally, logistic regression analysis
was used to examine the inﬂuence of individual variables on the
likelihood of death at 6 months. Only variables found signif-
icant in the univariate analysis were used as covariates in the
multivariate analysis.
The present study was approved by local Institutional
Review Boards and patient information was codiﬁed to ensure
anonymity. Baseline characteristics of included patients are
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summarized in Table 1. Age and gender were similar in the
three groups [P = not signiﬁcant (NS)], and there were no
differences among groups in cancer site and stage (P = NS).
PE was signiﬁcantly more prevalent in the group of patients
with an asymptomatic VTE than in the group with symptom-
atic VTE (85% vs. 20%, P < 0.001). All patients with
symptomatic or asymptomatic VTE were initially treated with
low-molecular-weight heparin (LMWH) or unfractionated
heparin. Long-term treatment with LMWH was used in
73.3% of patients with asymptomatic VTE and 78.3% of
patients with symptomatic VTE (P = NS), the remaining
patients were treated with warfarin. A minority of asymptom-
atic VTE patients were treated with prophylactic doses of
LMWH (6.7%). Total duration of treatment was similar
between the two groups of VTE patients. Although no
autopsies were performed, mortality was ascribed by the
treating oncologists to cancer progression in the large majority
of patients in the three groups.
Six-month mortality rates were signiﬁcantly higher in
patients with a VTE (both symptomatic and asymptomatic)
as compared with patients without a VTE (46.7% vs. 26.7%;
P = 0.007). Six-month mortality rates were similar in patients
with a symptomatic VTE and in patients with an asymptomatic
VTE (47.5% and 45.0%, respectively, P = 0.75) and were
signiﬁcantly higher in each of the two groups when compared
with patients without a VTE (P = 0.007 and P = 0.036,
respectively).
Atmultivariate analysis (after considering the VTE presence,
the VTE site and the presence of symptoms) VTE (either
symptomatic or asymptomatic) remained signiﬁcantly associ-
ated with an increased risk of 6-month mortality (OR 2.72;
95%CI 1.0, 7.43; P = 0.048), whereas the presence of symp-
toms and the VTE site did not (P = 0.90 and P = 0.55,
respectively).
A small group of studies have provided data on the natural
history of patients with an incidental PE [1–8,8–13], but only
one provided information on mortality rates. In the study by
OConnel et al. [8], patients with a PE had an increased risk of
death [hazard ratio (HR) 1.79; 95% conﬁdence interval (CI)
1.10, 2.90] and the presence of an incidental PE appeared to
confer a poorer survival (5 vs. 14 months; P = 0.0009) in
comparison to cancer patients without a VTE. The present
ﬁndings conﬁrm these results and, in addition, show for the ﬁrst
time that the prognosis of patients with cancer and an
asymptomatic VTE is similar to that in cancer patients with
a symptomatic VTE.
The present study has some limitations. First, the retrospec-
tive design limits inferences that can be drawn. Second, a
relatively small number of patients were included and thus CIs
around the association between VTE and mortality are wide.
To decrease the risk of bias in this small sample, we enrolled
patients consecutively and information on 6-monthmortality
was gathered for all patients. Third, we enrolled all cancer
types; different types of cancer may have a different natural
history independent of the presence of VTE. However, the
proportion of cancer types was not apparently different in the
three groups. As a result of the small numbers we were unable
to determine the magnitude of the association between an
asymptomatic VTE and each cancer type or between an
asymptomatic VTE and different cancer therapies. Fourth, we
cannot exclude that dissimilarity in the baseline characteristics
of these patients with a symptomatic and an asymptomatic
VTE may have inﬂuenced the results of the present study.
However, inmultivariate analysis these two groups appeared to
behave similarly. Finally, not all incidentally detected events
may have been truly asymptomatic. It is possible that signs or
symptoms of VTE may have existed in patients and were
missed by the clinical team.
Table 1 Baseline characteristics of included patients
Asympomatic VTE Symptomatic VTE No VTE
Number 60 120 60
Male sex, n (%) 31 (52) 65 (54) 29 (48)
Mean age (SD) 65.8 (10.9) 69.6 (11.5) 68.6 (10.2)
Advanced stage, n (%) 58 (96.6) 112 (93.3) 58 (96.6)
Cancer site 28 gastroenteric 37 gastroenteric 18 gastroenteric
8 pulmonary 17 pulmonary 14 pulmonary
6 lymphatic 15 lymphatic 5 lymphatic
6 breast 16 breast 12 breast
12 others 35 others 11 others
Venous thrombosis location 37 PE + DVT 20 PE + DVT –
9 isolated DVT 96 isolated DVT
14 isolated PE 4 isolated PE
Antithrombotic treatment 44 therapeutic LMWH 94 therapeutic LMWH
4 prophylactic LMWH 0 prophylactic LMWH
12 LMWH + warfarin 26 LMWH + warfarin
Cancer treatment 55 chemotherapy 101 chemotherapy 49 chemotherapy
2 hormonal therapy 7 hormonal therapy 6 hormonal therapy
15 radiotherapy 30 radiotherapy 12 radiotherapy
9 erythropoietin 13 erythropoietin 8 erythropoietin
Mortality, n (%) 27 (45) 57 (47.5) 16 (26.7)
VTE, venous thromboembolic events; PE, pulmonary embolism; DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin.
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In conclusion, our data suggest that the presence of an
asymptomatic VTE may have a clinical impact on the
prognosis of cancer patients, and that this impact is similar
to that seen in patients with a symptomatic VTE. Prospective
studies are warranted to conﬁrm our preliminary ﬁndings.
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von Willebrand disease (VWD) is the most common inherited
bleeding disorder caused by quantitative or qualitative deﬁ-
ciency of the von Willebrand factor (VWF) protein. VWD is
classiﬁed into three primary categories [1,2]. Type 1 and type 3
VWD are characterized by mild or severe quantitative
deﬁciencies of VWF, respectively. Type 2 VWD variants
(subtypes A, B, M and N) express qualitative deﬁciency
associated with a loss or gain of function of the VWF protein
[3]. A large diversity of mutations such as missense, nonsense
and splice site mutations, small deletions/insertions and large
deletions has been reported in the VWF gene database http://
www.vwf.group.shef.ac.uk. Large deletions are regarded as
being a rare cause of VWD, usually resulting in a complete lack
of VWFprotein [4]. Twelve large deletions, ranging in size from
a single exon to the entire gene, responsible for type 3 VWDare
reported up to now. Interestingly, a large deletion covering
all VWF A domains has been described for type 2A (http://
www.vwf.group.shef.ac.uk).
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